Company: DNLI
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001628280-25-008647
Chunk: 3

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 3
---
________</div>

#### INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE "

#### RISK FACTORS

#### " BEGINNING ON PAGE

#### 3
OF THIS PROSPECTUS AND IN ANY SIMILAR SECTION CONTAINED IN OR INCORPORATED BY REFERENCE HEREIN OR IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.

Our common stock is listed on The Nasdaq Global Select Market ("Nasdaq") under the symbol "DNLI." On February 25, 2025, the last reported sale price of our common stock on Nasdaq was $19.20 per share.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

#### The date of this prospectus is February 27, 2025.
#### ________________________________________

### TABLE OF CONTENTS
|                                     |     | Page |
| ABOUT THIS PROSPECTUS               |     |    1 |
| THE COMPANY                         |     |    2 |
| RISK FACTORS                        |     |    3 |
| USE OF PROCEEDS                     |     |    4 |
| DESCRIPTION OF SECURITIES           |     |    5 |
| PLAN OF DISTRIBUTION                |     |    6 |
| LEGAL MATTERS                       |     |    7 |
| EXPERTS                             |     |    7 |
| WHERE YOU CAN FIND MORE INFORMATION |     |    7 |
| INCORPORATION BY REFERENCE          |     |    8 |

### ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (the "SEC") as a "well-known seasoned issuer" as defined in Rule 405 under the Securities Act of 1933, as amended, using a "shelf" registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings as described in this prospectus. Each time that we offer and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering and, to the extent appropriate, any updates to the information about us contained in this